{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-294930","form_type":"8-K","ticker":"PFE","cik":"0000078003","company_name":"PFIZER INC","filed_at":"2023-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.991831+00:00","generated_at":"2026-06-07T13:13:40.120215+00:00","sec_items":["2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Pfizer completes $43B acquisition of Seagen at $229/share, expanding oncology portfolio","bullets":["Pfizer acquired Seagen for $229 per share in cash, total enterprise value of ~$43 billion.","Acquisition adds Seagen's four in-line ADC medicines (ADCETRIS, PADCEV, TIVDAK, TUKYSA) to Pfizer's oncology portfolio.","Pfizer's oncology pipeline doubles to 60 programs; now includes over 25 approved medicines across more than 40 indications.","To address FTC concerns, Pfizer irrevocably donates U.S. royalties from Bavencio (avelumab) to American Association for Cancer Research.","Pfizer expects oncology to be a significant growth driver and contribute to near- and long-term financial goals."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-294930","json":"https://secwatch.observer/filing/0001193125-23-294930.json","markdown":"https://secwatch.observer/filing/0001193125-23-294930.md","text":"https://secwatch.observer/filing/0001193125-23-294930.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/78003/000119312523294930/0001193125-23-294930-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/78003/000119312523294930/d553734d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T13:13:40.120215+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7705a59bc3796f6b2c01737251b0cc6b154e6fab","claim":"PFIZER INC completed an acquisition involving Seagen Inc. for $229.00 in cash per share, for a total enterprise value of approximately $43 billion (closed 2023-12-14).","evidence_excerpt":"Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/78003/000119312523294930/0001193125-23-294930-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Seagen Inc."},{"label":"Consideration","value":"$229.00 in cash per share, for a total enterprise value of approximately $43 billion"},{"label":"Closing","value":"2023-12-14"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}